TUC3PII-01_TU2670 Phase IIa Clinical Study
About the study
This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Independent Ethics Committee (IEC)-approved written informed consent/assent and privacy language as per national regulations must be voluntarily obtained from the subject.
- Premenopausal female subject, 18 to 45 years, inclusive
- Subject has moderate to severe endometriosis-related pain
EXCLUSION CRITERIA
Exclusion Criteria:
- Subject has used hormonal contraceptives or other drugs with effects on gynecological endocrinology within 12 weeks
- Subject has been nonresponsive to GnRH-agonist or antagonist therapy for the management of endometriosis.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Endometriosis
Age (in years)
18 - 45
Phase
Phase 2
Participants needed
80
Est. Completion Date
Dec 31, 2023
Treatment type
Interventional
Sponsor
TiumBio Co., Ltd.
ClinicalTrials.gov identifier
NCT05138562
Study number
TUC3PII-01
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?